Clinical Trial Update: Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating immunotherapy versus chemotherapy as adjuvant therapy for colon cancer with MSI-H or POLE/POLD1 mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Immunotherapy, Adjuvant Therapy | Phase 2 | Status: UNKNOWN